ISSN 2582 – 6050

Available Online at www.ijpba.info
International Journal of Pharmaceutical & Biological Archives 2024; 15(4):110-118

REVIEW ARTICLE

Molecular Insights into Triazole Resistance: A Comprehensive Review on Active Site Tyrosine Mutations in Fungal 14α-Demethylase

Gourav Babriwal[1], Rahul Meena[2], Bharat Chouhan[3], Vishal Nagar[4]

[1]Department of Pharmaceutical Chemistry, Kewal Shree Institute of Pharmacy, Indore, Madhya Pradesh, India, [2,3]Department of M. Pharm (Pharmaceutical Chemistry), Swami Vivekanand College of Pharmacy, Indore, Madhya Pradesh, India, [4]Department of Pharmaceutical Chemistry, Government Holkar (Model, Autonomous) Science College, Indore, Madhya Pradesh, India

Received: 12-10-2024; Revised: 09-11-2024; Accepted: 03-12-2024

ABSTRACT

Background: Triazoles are essential antifungal agents used in clinical and agricultural contexts to manage fungal infections. However, their efficacy is increasingly compromised by the emergence of resistant fungal strains. A key mechanism of resistance involves mutations in the lanosterol 14α-demethylase enzyme (*CYP51*), particularly at conserved residues such as the active site tyrosine. These mutations disrupt triazole binding, leading to reduced antifungal susceptibility. **Objective:** This review provides a detailed examination of the molecular mechanisms underlying triazole resistance, with a focus on mutations affecting the conserved active site tyrosine in fungal *CYP51*. It discusses structural insights, clinical implications, and potential strategies to counteract resistance. **Key Findings:** The active site tyrosine in *CYP51* plays a critical role in maintaining enzyme function and facilitating triazole binding. Mutations in this residue alter the enzyme's structure, reducing the binding affinity of triazoles and conferring resistance. These mutations are prevalent in both clinical and agricultural fungal strains, posing significant challenges for treatment and crop protection. Advances in structural biology and molecular diagnostics have enhanced our understanding of these mutations, enabling better monitoring and potential drug development. **Conclusion:** Active site tyrosine mutations represent a pivotal mechanism in triazole resistance, emphasizing the need for novel therapeutic approaches. Targeted drug design and combination therapies hold promise in overcoming resistance and safeguarding triazole efficacy. This review highlights the importance of continued research and global surveillance to mitigate the impact of antifungal resistance.

Keywords: *CYP51* mutations, fungal sterol biosynthesis, lanosterol 14α-demethylase, sterol 14α-demethylase inhibitors, triazole resistance

INTRODUCTION

Fungal infections pose a significant global health challenge, affecting millions of individuals annually and contributing to substantial morbidity and mortality. These infections range from superficial conditions like dermatophytosis to life-threatening systemic diseases such as invasive aspergillosis and candidiasis. Immunocompromised individuals, including those undergoing organ transplants, chemotherapy, or suffering from HIV/AIDS, are particularly vulnerable to invasive fungal infections. In addition to human health, fungal pathogens are a major concern in agriculture, causing devastating losses to crops and threatening food security.[1] Antifungal therapies are critical for managing fungal infections. The four main classes of antifungal drugs polyenes, echinocandins, allylamines, and azoles target specific components

***Corresponding Author:**
Gourav Babriwal
E-mail: gouravbabriwal1875@gmail.com

of fungal cells to inhibit growth or promote cell death. Among these, azoles, particularly triazoles such as fluconazole, itraconazole, voriconazole, and posaconazole, are widely used due to their broad spectrum of activity, oral bioavailability, and relatively favorable safety profiles. Triazoles inhibit lanosterol 14α-demethylase (*CYP51*), a key enzyme in the fungal ergosterol biosynthesis pathway, leading to disruption of the fungal cell membrane.[2]

In clinical settings, triazoles are first-line treatments for many invasive fungal infections, while in agriculture, they are extensively used as fungicides to protect crops from fungal pathogens. Despite their efficacy, the overuse and misuse of triazoles in both domains have driven the emergence of resistant fungal strains. Triazole resistance compromises therapeutic outcomes in clinical settings and diminishes the effectiveness of crop protection strategies, thereby exacerbating public health and food security challenges.[3]

The growing concern over triazole resistance is fueled by the limited availability of alternative antifungal agents and the slow pace of new antifungal drug development. Resistance mechanisms in fungi are complex, with mutations in *CYP51*, especially at conserved active site residues, being a significant contributor. These mutations alter the enzyme's structure, reducing the binding affinity of triazoles and rendering them less effective. The spread of resistant strains, such as azole-resistant *Aspergillus fumigatus*, highlights the urgent need for comprehensive surveillance, effective stewardship of existing antifungal agents, and the development of innovative therapies.[4]

This review explores the molecular basis of triazole resistance, with a focus on the role of conserved active site tyrosine mutations in fungal *CYP51*. By understanding these mechanisms, we can better address the challenges posed by antifungal resistance in clinical and agricultural contexts.

CYP51: STRUCTURE AND FUNCTION

CYP51, commonly referred to as *CYP51*, is a critical enzyme in the sterol biosynthesis pathway of fungi. As a member of the cytochrome P450 superfamily, *CYP51* catalyzes the demethylation of lanosterol at the 14α position, an essential step in the production of ergosterol. Ergosterol is a key component of fungal cell membranes, contributing to membrane fluidity, integrity, and function. The disruption of this pathway compromises cell viability, making *CYP51* an ideal target for antifungal agents like triazoles.[5]

Role of *CYP51* in Fungal Sterol Biosynthesis

The sterol biosynthesis pathway is vital for fungal growth and survival, as ergosterol serves a role analogous to that of cholesterol in mammalian cells. In fungi, lanosterol undergoes a series of enzymatic modifications, with *CYP51* catalyzing the removal of the 14α-methyl group. This reaction is crucial because the accumulation of 14-methylated sterols disrupts membrane functions, rendering the cell unable to grow or divide properly.

Inhibiting *CYP51* halts ergosterol biosynthesis, leading to ergosterol depletion and the accumulation of toxic sterol intermediates. This dual effect disrupts membrane integrity, increases permeability, and ultimately causes cell death. Triazoles, a subclass of azole antifungals, exploit this vulnerability, making *CYP51* inhibition a cornerstone of antifungal therapy.[7]

Structural Features of *CYP51*

The structure of *CYP51* is highly conserved across fungal species, reflecting its essential biological role. It consists of a globular protein with a central heme-binding domain, which houses an iron atom that facilitates catalytic activity. The heme group is coordinated by a cysteine residue, a hallmark of all cytochrome P450 enzymes [Figure 1].[8]

Key structural features of *CYP51* include:

1. Substrate-binding pocket: The active site of *CYP51* is a hydrophobic pocket that accommodates lanosterol and other sterol substrates. The shape and chemical properties of this pocket are critical for substrate specificity.
2. Conserved active site tyrosine: A tyrosine residue in the active site is essential for enzyme function. This residue forms stabilizing



Figure 1: Lanosterol 14α-demethylase[6]



Figure 2: Crystal structure of lanosterol 14-alpha demethylase with intact transmembrane domain bound to itraconazol[10]

interactions with both the substrate and the inhibitor, influencing binding affinity. Mutations in this tyrosine are often implicated in triazole resistance.

3. Membrane association domain: *CYP51* is embedded in the endoplasmic reticulum membrane through a hydrophobic region, allowing it to access sterol intermediates within the lipid bilayer.

MECHANISMS OF TRIAZOLE BINDING AND INHIBITION

Triazoles inhibit *CYP51* by directly binding to the enzyme's heme iron through their azole moiety [Figure 2]. This interaction displaces the water molecule that normally coordinates the iron, disrupting the enzyme's catalytic cycle. The result is a stable *CYP51*-triazole complex that prevents substrate turnover, effectively halting ergosterol production.[9]

The mechanism of triazole binding can be summarized in three key steps:

1. Entry into the active site: Triazoles diffuse into the active site of *CYP51* through a hydrophobic channel. The structural complementarity between the inhibitor and the active site ensures selective binding.
2. Interaction with heme iron: The nitrogen atom in the triazole ring coordinates with the heme iron, forming a strong bond that disrupts normal enzyme function. This coordination is critical for inhibition.
3. Stabilizing interactions: Additional interactions between the triazole molecule and amino acid residues within the active site, including hydrogen bonds and van der Waals forces, further stabilize the inhibitor-enzyme complex.

While triazoles are highly effective inhibitors of *CYP51*, their efficacy can be compromised by structural changes in the enzyme. Mutations in the active site, particularly in residues such as the conserved tyrosine, alter the shape or charge distribution of the substrate-binding pocket. These changes reduce the binding affinity of triazoles without significantly impairing the enzyme's catalytic function.[11]

MECHANISMS OF TRIAZOLE RESISTANCE

Triazole resistance in fungi has become a significant concern in both clinical and agricultural settings. The mechanisms underlying this resistance are complex andmultifaceted,ofteninvolvinggenetic,biochemical, and physiological adaptations. These mechanisms enable fungi to survive despite the presence of triazole antifungal agents, ultimately reducing treatment efficacy and crop protection.[12]

General Mechanisms of Antifungal Resistance

Antifungal resistance arises through various strategies that fungi employ to evade the effects of antifungal drugs [Figures 3 and 4]. Common mechanisms include:[14]

1. Efflux pump overexpression: Fungi upregulate efflux pumps, such as ATP-binding cassette transporters and major facilitator superfamily transporters, which actively expel antifungal drugs from the cell, reducing intracellular drug concentrations and minimizing their effects.
2. Altered drug target expression: Fungi can increase the production of drug target enzymes, effectively diluting the inhibitory effects of antifungal agents.
3. Compensatory pathways: Resistance may involve the activation of alternative biosynthetic pathways that bypass the inhibited enzyme or mitigate the impact of ergosterol depletion.
4. Biofilm formation: Fungi growing in biofilms exhibit heightened resistance to antifungal drugs due to their dense extracellular matrix and unique microenvironment, which restrict drug penetration and activity.
5. Stress response activation: Cellular stress responses, such as the heat shock protein pathway, can enhance fungal survival under antifungal treatment by stabilizing key proteins and membranes.



Figure 3: Mechanisms of triazole resistance[13]



Figure 4: General mechanisms of antifungal resistance[15]

Specific Role of Mutations in *CYP51* in Resistance Development

One of the most well-studied mechanisms of triazole resistance is the emergence of mutations in *CYP51*, the primary target of triazole antifungals. *CYP51* mutations alter the structure of the enzyme, particularly the active site, and reduce the binding affinity of triazoles while maintaining enzymatic activity.

Key mutations in *CYP51* include:

1. Active site alterations: Substitutions in conserved residues, such as the active site tyrosine, disrupt the interaction between triazoles and the heme group in *CYP51*. These changes reduce triazole binding and render the drug less effective.
2. Structural modifications: Mutations in other regions of *CYP51* can lead to conformational changes that indirectly impact triazole binding.
3. Overexpression of *CYP51*: Some fungal strains increase *CYP51* expression, allowing sufficient enzyme activity despite partial inhibition by triazoles.

The combination of *CYP51* mutations and other resistance mechanisms often results in multidrug resistance, making treatment even more challenging. Monitoring and understanding these mechanisms are crucial for developing novel antifungal strategies and preserving the efficacy of existing drugs.[16]

THE ROLE OF ACTIVE SITE TYROSINE IN *CYP51*

Conserved Nature of the Active Site Tyrosine Residue

The active site tyrosine residue in *CYP51* is a highly conserved amino acid across fungal species, underscoring its critical role in enzyme function. This tyrosine, located within the substrate-binding pocket, interacts directly with the sterol substrate and antifungal inhibitors such as triazoles. Its evolutionary conservation indicates that even minor alterations in this residue can profoundly affect the enzyme's activity and its interactions with ligands.[17]

Functional Importance of Tyrosine in Enzyme Activity and Triazole Binding[18]

The active site tyrosine plays a dual role in *CYP51*:

1. Catalytic function: During sterol demethylation, the tyrosine residue contributes to the correct positioning of lanosterol within the active site. It facilitates the interaction between the sterol substrate and the heme group, ensuring efficient catalysis.
2. Triazole binding: The tyrosine residue also plays a pivotal role in stabilizing the binding of triazole antifungals. Triazoles coordinate with the heme iron at the active site and form additional stabilizing interactions with surrounding amino acids, including the tyrosine. These interactions enhance the potency of triazoles as inhibitors of *CYP51*.

Mutational Analysis and Its Effects on Enzyme Function

Mutational studies have demonstrated the importance of the active site tyrosine in both enzyme activity and drug binding. Substitution of this residue with other amino acids, such as phenylalanine or histidine, can lead to:

- Altered catalysis: Changes in the active site geometry disrupt the enzyme's ability to bind and process lanosterol, leading to reduced catalytic efficiency.
- Reduced triazole binding affinity: Mutations weaken the stabilizing interactions between *CYP51* and triazoles, resulting in diminished drug efficacy and resistance development.

Such mutations often arise in resistant fungal strains and represent a major challenge in managing antifungal resistance.[19]

MOLECULAR BASIS OF ACTIVE SITE TYROSINE MUTATIONS

Common Mutations Observed in Resistant Fungal Strains[20]

Several mutations in the active site tyrosine of *CYP51* have been identified in triazole-resistant fungal strains. Common substitutions include:

1. Tyrosine to phenylalanine (Y132F): Frequently observed in *A. fumigatus*, this mutation retains the hydrophobicity of the active site but eliminates the hydroxyl group, critical for forming hydrogen bonds with triazoles.
2. Tyrosine to histidine (Y132H): Seen in other fungal species, this mutation introduces a polar group that alters the binding environment of the active site, further compromising triazole binding.
3. Tyrosine to serine (Y132S): Occasionally reported, this mutation introduces a smaller, polar residue, drastically changing the steric and chemical properties of the active site.

Structural and Biochemical Changes Caused by Tyrosine Mutations

Mutations in the active site tyrosine lead to several structural and biochemical changes in *CYP51*:

1. Active site remodeling: Substitutions alter the shape and size of the substrate-binding pocket, potentially affecting substrate orientation and catalytic efficiency.
2. Disrupted triazole coordination: The loss or modification of hydrogen-bonding interactions between triazoles and the active site reduces the binding affinity of the drug.
3. Heme accessibility: Changes in the tyrosine residue can influence the accessibility and alignment of the heme group, further impairing enzyme function and drug inhibition.

These alterations allow the mutant *CYP51* enzyme to maintain its physiological role in sterol biosynthesis while evading inhibition by triazoles.[21]

Implications for Triazole Binding and Efficacy[22]

The emergence of active site tyrosine mutations has profound implications for the efficacy of triazole antifungals:

1. Reduced drug potency: Mutations decrease the inhibitory effect of triazoles, requiring higher drug concentrations to achieve the same level of fungal inhibition. This can lead to therapeutic failure in clinical settings.
2. Cross-resistance: Tyrosine mutations often confer resistance to multiple triazole drugs due to their shared mode of action, limiting treatment options.
3. Persistence of resistant strains: The selective pressure exerted by triazole use in clinical and agricultural environments promotes the survival and spread of resistant strains, exacerbating the resistance problem globally.

Addressing the Challenge of Tyrosine Mutations

Understanding the molecular basis of active site tyrosine mutations is critical for developing strategies to overcome triazole resistance. Potential approaches include:

- Structure-based drug design: Designing novel triazole derivatives or alternative inhibitors that can bypass the resistance conferred by tyrosine mutations.
- Combination therapies: Using triazoles in combination with other antifungal agents to target multiple pathways and reduce the selective pressure for resistance.
- Surveillance and stewardship: Monitoring resistant strains and optimizing antifungal use to minimize the emergence of new mutations.

In conclusion, the active site tyrosine in *CYP51* plays a critical role in enzyme activity and triazole binding. Mutations in this residue represent a key mechanism of resistance, highlighting the need for innovative antifungal strategies to address this growing challenge.[23]

DETECTION AND MONITORING OF RESISTANCE

Techniques for Identifying *CYP51* Mutations

The identification of *CYP51* mutations in resistant fungal strains is crucial for understanding and mitigating triazole resistance. Several advanced molecular techniques are employed:[24]

1. DNA sequencing: Whole-genome sequencing and targeted sequencing of the *CYP51* gene are gold-standard methods. These techniques allow precise identification of point mutations, insertions, or deletions in the gene.
2. Polymerase chain reaction (PCR)-based assays: Real-time PCR and allele-specific PCR are

widely used to detect known mutations rapidly. These methods are cost-effective and suitable for high-throughput surveillance.
3. Molecular diagnostics: Techniques such as reverse transcription-PCR and digital droplet PCR provide sensitive and quantitative detection of mutations.
4. CRISPR-cas tools: Emerging approaches leverage CRISPR-based diagnostics for rapid and specific mutation detection.
5. Phenotypic testing: Coupled with molecular diagnostics, phenotypic assays assess fungal growth in the presence of triazoles, indirectly indicating resistance.

Challenges in Monitoring and Surveillance[25]

1. Genetic diversity: The variability of *CYP51* mutations across species and strains complicates the development of universal diagnostic tools.
2. Resource constraints: Limited access to sequencing technologies and expertise in resource-limited settings hinders comprehensive surveillance.
3. Environmental reservoirs: Monitoring resistant strains in environmental reservoirs, particularly agricultural settings, is challenging due to widespread triazole use.
4. Global Spread: The cross-border movement of resistant fungal strains, driven by trade and travel, underscores the need for coordinated international surveillance.

STRATEGIES TO OVERCOME TRIAZOLE RESISTANCE[26,27]

Development of New Antifungal Agents Targeting *CYP51*

1. Next-generation azoles: Structural modifications to existing triazoles aim to enhance binding affinity to mutant *CYP51* enzymes while minimizing off-target effects.
2. Non-triazole inhibitors: Alternative classes of *CYP51* inhibitors, such as tetrazoles or other azole analogs, offer potential for bypassing resistance mechanisms.
3. Broad-spectrum antifungals: Novel compounds targeting additional fungal pathways may complement or replace *CYP51* inhibitors.

Combination Therapies to Counteract Resistance

1. Drug synergy: Combining triazoles with other antifungal classes, such as echinocandins or polyenes, enhances efficacy and reduces the likelihood of resistance.
2. Resistance modulators: Small molecules that inhibit efflux pumps or stress response pathways can restore triazole sensitivity in resistant strains.
3. Immunotherapy: Enhancing host immunity through vaccines or immune-boosting agents can improve outcomes alongside antifungal therapy.

Potential for Molecular Inhibitors or Alternative Approaches

1. Heme mimics: Molecules that disrupt the heme group's interaction with *CYP51* may serve as potent inhibitors.
2. RNA-based therapies: Gene silencing approaches, such as RNA interference, could specifically target *CYP51* transcripts in resistant fungi.
3. Nanotechnology: Nanocarrier-based delivery systems improve the bioavailability and targeted action of antifungals.

FUTURE DIRECTIONS IN RESEARCH[28,29]

Gaps in Understanding of *CYP51* Structure-Function Relationships

While significant progress has been made, gaps remain in understanding how mutations in non-catalytic regions influence enzyme function and resistance. Elucidating these nuances is critical for next-generation drug design.

Advances in Structural Biology and Drug Design

1. Cryo-Electron Microscopy (Cryo-EM): Advances in Cryo-EM enable high-resolution

visualization of *CYP51* mutations and their impact on drug binding.
2. AI-driven drug discovery: Machine learning models are being used to predict mutation impacts and design tailored inhibitors.
3. Structure-based virtual screening: Computational methods identify novel compounds that effectively target mutant *CYP51*.

Potential Areas for Therapeutic Innovation

1. Targeting biofilms: Developing agents that penetrate fungal biofilms or disrupt their formation offers new therapeutic avenues.
2. Environmental strategies: Reducing the agricultural use of triazoles or developing biodegradable fungicides could limit environmental selection pressure.
3. Host-fungus interactions: Understanding host-pathogen dynamics may reveal novel targets for antifungal intervention.

CONCLUSION

Triazole resistance, driven by mutations in *CYP51*, poses a growing threat to the effective management of fungal infections in clinical and agricultural settings. The conserved nature of *CYP51*, particularly its active site, makes it a critical target for antifungal therapies but also a hotspot for resistance development. Advances in molecular diagnostics, structural biology, and drug discovery have significantly enhanced our understanding of resistance mechanisms and potential strategies to counteract them. To overcome resistance, a multifaceted approach is essential, encompassing the development of novel antifungal agents, combination therapies, and alternative strategies like molecular inhibitors and immunotherapy. Global surveillance and stewardship programs are equally critical to monitor resistant strains and mitigate the spread of resistance.

REFERENCES

1. Brun S, Bergès T, Poupard P. Mechanisms of azole resistance in *Candida albicans* isolates from HIV-infected patients. Antimicrob Agents Chemother 2004;48:1513-22.
2. Odds FC, Brown AJ, Gow NA. Antifungal agents: Mechanisms of action. Trends Microbiol 2003;11:272-9.
3. Rodriguez-Tudela JL, Almirante B, Rodriguez-Pardo D. Epidemiology and prognosis of candidemia in elderly patients. Clin Microbiol Infect 2008;14:608-15.
4. Becher R, Wirsel SG. Fungal cytochrome P450 monooxygenases: Diversity, function, and potential for application. Appl Microbiol Biotechnol 2012;95:885-99.
5. Howard SJ, Cerar D,Anderson MJ,AlbarragA, Fisher MC, Pasqualotto AC, *et al*. Frequency and evolution of azole resistance in *Aspergillus fumigatus* associated with treatment failure. Emerg Infect Dis 2009;15:1068-76.
6. Available from: https://upload.wikimedia.org/wikipedia/commons/thumb/b/b7/structure_of_lanosterol_14_%ce%b1-demethylase_%28cyp51%29.png/220px-structure_of_lanosterol_14_%ce%b1-demethylase_%28cyp51%29.png
7. Maertens JA. History of the development of azole derivatives. Clin Microbiol Infect 2004;10:1-10.
8. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, Melchers WJ, Verweij PE, Cuenca-Estrella M, *et al*. A new mutation in the *cyp51*A gene of *Aspergillus fumigatus* associated with triazole resistance. Antimicrob Agents Chemother 2007;51:1897-904.
9. Perea S, Lopez-Ribot JL, Kirkpatrick WR, McAtee RK, Santillán RA, Martínez M, *et al*. Molecular mechanisms of resistance to fluconazole in *Candida albicans* clinical isolates.AntimicrobAgents Chemother 2001;45:2676-84.
10. Available from: https://www.rcsb.org/structure/5eqb
11. Vanden Bossche H, Marichal P, Gorrens J. Biochemical approaches to selective antifungal therapy. Biochem Soc Transactions 1990;18:56-9.
12. Denning DW,Venkateswarlu K, Oakley KL,Anderson MJ, Manning NJ, Stevens DA, *et al*. Itraconazole resistance in *Aspergillus fumigatus.* Antimicrob Agents Chemother 1997;41:1364-68.
13. Available from:https://www.researchgate.net/publication/336864707/figure/fig3/as:821315275599873@1572828229449/mechanisms-of-triazoles-resistance-in-aspergillus-spp-cdr1b-abc-efflux-transporter.jpg
14. Camps SM, RijsAJ, Klaassen CH, Meis JF, O'Gorman CM, Dyer PS, *et al*. Molecular epidemiology of azole resistance in *Aspergillus fumigatus* in the Netherlands. Antimicrob Agents Chemother 2012;56:589-95.
15. Available from: https://encrypted-tbn0.gstatic.com/images?q=tbn: ANd9GcQCOduE4-K8-eOtHM2hhVd9-fugYyTcxAql7Q&s
16. Hof H. Critical points in the development of azole antifungals. Mycoses 2001;44:385-93.
17. Marichal P, Vanden Bossche H, Odds FC. Molecular biologyofantifungalresistance.Mycoses1999;42:415-21.
18. Bowyer P, Mosquera J, Anderson M. Azole antifungal resistancein*Aspergillusfumigatus*mutants:Transcriptome analysis. Fungal Genet Biol 2011;48:106-15.

19. Eddouzi J, Parker JE, Vale-Silva LA. Molecular mechanisms of *Candida albicans* resistance to azoles. Antimicrob Agents Chemother 2013;57:5323-36.
20. Zhang J, Liu M, Xu Z. Mechanistic insights into *CYP51* and resistance to azole antifungals in pathogenic fungi. Front Microbiol 2019;10:682.
21. Espinel-Ingroff A, Cuenca-Estrella M, Fothergill A. *Aspergillus fumigatus* resistance mechanisms to triazole antifungals. Med Mycol 2005;43:S295-307.
22. Lepesheva GI, Waterman MR. Sterol 14α-demethylase cytochrome P450 and inhibitors of sterol biosynthesis. Biochim Biophys Acta 2007;1771:663-86.
23. Fisher MC, Hawkins NJ, Sanglard D, Gurr SJ. Worldwide emergence of antifungal resistance. Science 2018;360:739-42.
24. Parker JE, Warrilow AG, Price CL. Resistance mechanisms in azole-resistant *Aspergillus fumigatus* mutants. PLoS Pathog 2014;10:e1004175.
25. Prasad R, Kapoor K. Multidrug resistance in yeast *Candida*. Int Rev Cytol 2005;242:215-48.
26. Perlin DS. Mechanisms of echinocandin antifungal drug resistance. Ann N Y Acad Sci 2015;1354:1-11.
27. Sanglard D, Ischer F, Calabrese D. Mechanisms of resistance to azole antifungal agents in *Candida albicans*. Antimicrob Agents Chemother 1999;43:2401-8.
28. Verweij PE, Chowdhary A, Melchers WJ. Azole resistance in *Aspergillus fumigatus:* A growing public health concern. Curr Opin Infect Dis 2016;29: 493-500.
29. Slaven JW, Anderson MJ, Sanglard D. Increased incidence of azole-resistant *Aspergillus fumigatus*. Antimicrob Agents Chemother 2002;46:1616-20.